Medically reviewed by Dr. Pedro Martinez-Clark, MD and Dr. William O'Neill, MD. Last reviewed: July 2026.
Colombia has become the gold standard for first-in-human medical device studies in Latin America. With INVIMA ethics approval in 4–6 weeks, per-patient costs of $15K–$25K, and bioaccess®'s 15+ years of on-the-ground experience, Colombia delivers FDA-submissible clinical data faster and more affordably than any US or EU pathway.
Colombia's regulatory ecosystem, led by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), has established itself as the most efficient pathway for first-in-human medical device studies in the Americas. INVIMA holds Level 4 regulatory authority status — the highest designation in Latin America — meaning device approvals carry significant credibility with the FDA and EMA.
bioaccess® has been operating in Colombia since 2010, building the region's most extensive network of ISO 14155 certified clinical sites across Bogotá, Cali, Medellín, and Barranquilla. Our team has secured INVIMA approval for 30+ first-in-human device studies, spanning structural heart, vascular, neurotechnology, orthopedics, ophthalmology, and gene therapy. Key clients like Mitralign (acquired by Edwards Lifesciences), PAVmed, Avantec Vascular, and Axoft have used Colombian FIH data as the clinical cornerstone for FDA submissions and strategic exits.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Colombian studies conducted under ISO 14155 guidelines with proper INVIMA oversight. bioaccess® designs every protocol with FDA submission in mind — including electronic data capture, structured adverse event reporting, and core lab integration when required. (eligibility for FDA submission and review — not a guarantee of clearance or approval)
INVIMA is Colombia's national regulatory authority for drugs, devices, and biologics. For clinical investigations, sponsors submit a protocol package including the investigator brochure, informed consent, insurance certificate, and ethics committee approval. INVIMA reviews run concurrently with ethics committee review, and bioaccess® typically achieves full regulatory clearance within 4–6 weeks. Colombia does not require a separate IND/IDE application for early feasibility studies.
Colombia's institutional ethics committees (Comités de Ética en Investigación) are INVIMA-accredited and follow ISO 14155 E6(R2) guidelines. Review timelines average 4–6 weeks for first-in-human device studies. bioaccess® maintains pre-established relationships with ethics committees at our 20+ partner hospitals, enabling streamlined submissions and rapid approvals.
bioaccess® operates 20+ pre-qualified clinical trial sites across Colombia's major medical centers. Bogotá offers the largest concentration of tertiary care hospitals with sub-specialty expertise. Cali is home to world-class interventional cardiology and vascular surgery programs. Medellín provides advanced neurosurgery and orthopedic capabilities. Barranquilla has emerged as a hub for cardiovascular device studies with experienced interventional radiologists.
Colombian FIH data is eligible for FDA submission and review when studies comply with ISO 14155 guidelines, have proper ethics committee and INVIMA oversight, and include adequate safety monitoring. bioaccess® has successfully supported FDA pre-submission meetings using Colombian FIH data for multiple clients, including structural heart devices, vascular access systems, and neurotechnology platforms.
| Metric | Colombia 🇨🇴 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory/ethics approval | 4–6 weeks (INVIMA + EC concurrent) | 6–12 months (IDE + IRB) | 3–6 months (per-country CA + EC) |
| Cost per patient | $15K–$25K | $40K–$75K | $35K–$60K |
| Separate IDE/IND for EFS | Not required | Required | Varies by country |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Time zone vs. US East Coast | Same (EST/EDT) | Same | +5 to +6 hours |
| Regulatory authority maturity | INVIMA — PAHO/WHO Level 4 | FDA | EMA / national CAs |
| Typical 10-patient FIH timeline to first enrollment | 2–3 months | 9–15 months | 6–10 months |
Ranges reflect bioaccess® first-in-human medical device studies. Actual costs and timelines vary by device complexity, therapeutic area, and monitoring requirements.
INVIMA approval typically takes 4–6 weeks when submitted concurrently with ethics committee review. bioaccess® handles the entire submission process, including protocol translation, insurance procurement, and regulatory correspondence. Our track record includes 30+ successful INVIMA approvals for FIH device studies.
Per-patient costs in Colombia range from $15,000–$25,000 depending on device complexity, therapeutic area, and monitoring requirements. A typical 10-patient FIH study costs approximately $250K–$350K — compared to $750K–$1.5M in the United States. These savings preserve critical runway for venture-backed startups.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from studies conducted in compliance with ISO 14155 guidelines. bioaccess® designs all Colombian studies with FDA submission in mind, including proper informed consent, adverse event reporting, electronic data capture, and INVIMA regulatory oversight.
Colombia excels in structural heart (mitral/aortic valve), vascular & interventional (coronary, peripheral), neurotechnology (brain-computer interfaces, nerve repair), orthopedics/spine, ophthalmology, and gene therapy. bioaccess® has completed FIH studies across all of these areas with investigators who hold international training credentials.
Yes. bioaccess® has maintained a physical presence in Colombia since 2010, with team members in Bogotá and Cali. Our Colombian operations team includes regulatory affairs specialists, clinical research associates, and site coordinators who manage every aspect of your study on the ground.
Colombia offers the fastest regulatory pathway (4–6 weeks vs. 8–16 weeks for ANVISA/COFEPRIS), the most competitive per-patient costs, and bioaccess®'s deepest operational experience. Brazil offers larger patient populations for specific indications, while Mexico provides proximity advantages and a reliance framework. bioaccess® recommends the optimal country based on your specific device and timeline.
All countries we serve · Contact bioaccess® · First-in-Human CRO